STOCK TITAN

Director at NeuroPace (NPCE) receives 865-share stock grant

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

LACOB JOSEPH reported acquisition or exercise transactions in this Form 4 filing.

NeuroPace Inc director Joseph Lacob received a grant of 865 shares of common stock at $13.00 per share as part of non-employee director compensation in lieu of quarterly retainer fees. Following this award, he holds 14,754 shares directly, plus indirect holdings through Lacob Ventures LLC and LCT18 Investments.

Positive

  • None.

Negative

  • None.
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LACOB JOSEPH

(Last)(First)(Middle)
C/O NEUROPACE, INC.
455 N. BERNARDO AVENUE

(Street)
MOUNTAIN VIEW CALIFORNIA 94043

(City)(State)(Zip)

UNITED STATES

(Country)
2. Issuer Name and Ticker or Trading Symbol
NeuroPace Inc [ NPCE ]
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
03/20/2026
6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock03/20/2026A865(1)A$1314,754D
Common Stock128,174ISee footnote(2)
Common Stock223,554ISee footnote(3)
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Explanation of Responses:
1. These shares were issued to the Reporting Person pursuant to the Issuer's non-employee director compensation policy in lieu of quarterly retainer fees.
2. Shares are held by Lacob Ventures LLC.
3. Shares are held by LCT18 Investments.
Remarks:
/s/ Leah Akin, Attorney-in-Fact03/24/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did NPCE director Joseph Lacob report?

Joseph Lacob reported receiving a grant of 865 NeuroPace (NPCE) common shares at $13.00 per share. The grant was issued as part of the company’s non-employee director compensation program in lieu of regular quarterly cash retainer fees.

How many NeuroPace (NPCE) shares does Joseph Lacob now hold directly?

After the reported grant, Joseph Lacob directly holds 14,754 shares of NeuroPace common stock. This direct position reflects the inclusion of the newly awarded 865-share grant he received as non-employee director compensation on the indicated transaction date.

How was Joseph Lacob’s NPCE stock grant structured?

The filing states that 865 shares of NeuroPace common stock were issued at $13.00 per share. These shares were granted under the company’s non-employee director compensation policy, specifically in lieu of quarterly retainer fees normally paid to board members in cash.

Does Joseph Lacob hold additional NPCE shares indirectly?

Yes. The filing shows indirect holdings of NeuroPace shares held through Lacob Ventures LLC and LCT18 Investments. One line reports 128,174 shares and another 223,554 shares as indirect positions, both referenced to these entities in the accompanying footnotes.

Is Joseph Lacob’s NPCE stock grant an open-market purchase?

No. The 865-share transaction is coded as an “A” grant/award, meaning it is a compensation-related share award, not an open-market purchase. It was issued under the non-employee director compensation policy rather than bought on the open market.
Neuropace Inc

NASDAQ:NPCE

View NPCE Stock Overview

NPCE Rankings

NPCE Latest News

NPCE Latest SEC Filings

NPCE Stock Data

446.76M
25.96M
Medical Devices
Surgical & Medical Instruments & Apparatus
Link
United States
MOUNTAIN VIEW